Search | Clinical Trials Finder

Conditions: Cancer
Interventions: Retrospective Populations; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2032
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Soft Tissue Sarcoma, Fibrous Histiocytoma, Liposarcoma, Leiomyosarcoma, Fibrosarcoma, Synovial Sarcoma
Interventions: Bevacizumab, Radiation Therapy, Surgery; Drug · Radiation · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neoplasms, Prostate
Interventions: dutasteride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 2,795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 73
States / cities: Anchorage, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 68 more

Conditions: Thyroid Nodules, Pulsed Field Ablation
Interventions: Questionnaire; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neoplasm, Pancreatic Cancer
Interventions: [18F]-FDG PET/CT imaging; Radiation
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage 0 Hypopharyngeal Cancer, Stage 0 Laryngeal Cancer, Stage 0 Lip and Oral Cavity Cancer, Stage I Adenoid Cystic Carcinoma of the Oral Cavity, Stage I Mucoepidermoid Carcinoma of the Oral Cavity, Stage I Squamous Cell Carcinoma of the Hypopharynx, Stage I Squamous Cell Carcinoma of the Larynx, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Verrucous Carcinoma of the Larynx, Stage I Verrucous Carcinoma of the Oral Cavity, Stage II Adenoid Cystic Carcinoma of the Oral Cavity, Stage II Mucoepidermoid Carcinoma of the Oral Cavity, Stage II Squamous Cell Carcinoma of the Hypopharynx, Stage II Squamous Cell Carcinoma of the Larynx, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Verrucous Carcinoma of the Larynx, Stage II Verrucous Carcinoma of the Oral Cavity, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions: transoral robotic surgery, quality of life assessment; Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Nonmalignant Neoplasm, Tuberous Sclerosis, Lymphangioleimyomatosis, Kidney Angiomyolipoma
Interventions: Rapamycin; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 3 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 7
States / cities: Loma Linda, California • Hartford, Connecticut • Boston, Massachusetts + 4 more

Conditions: Prostate Carcinoma, Benign Prostatic Hyperplasia
Interventions: Merit Medical Embospheres, Radiation Therapy; Device · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 50 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Benign Neoplasms, Brain, Brain Cancer, Brain Neoplasms, Benign, Brain Neoplasms, Malignant, Brain Tumor, Primary, Brain Tumor, Recurrent, Brain Tumors, Intracranial Neoplasms, Neoplasms, Brain, Neoplasms, Intracranial, Primary Brain Neoplasms, Primary Malignant Brain Neoplasms, Primary Malignant Brain Tumors, Gliomas, Glioblastoma
Interventions: 5-ALA (Gliolan); Drug
Lead sponsor: Constantinos Hadjipanayis; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Atlanta, Georgia • Ann Arbor, Michigan • Detroit, Michigan + 1 more

Conditions: Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma
Interventions: Panitumumab-IRDye800; Drug
Lead sponsor: Eben Rosenthal; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Non-Melanoma Skin Cancer (NMSC), Benign Skin Growth
Interventions: Ameluz 10% Topical Gel, Protoporphyrin IX; Drug · Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions: biologic sample preservation procedure, cytology specimen collection procedure; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 15,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2040
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Neoplasms
Interventions: Contrast Enhanced Digital Mammography; Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 30 Years to 80 Years · Female only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Malignant Melanoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Atypical Nevi, Congenital Nevi, Seborrheic Keratosis, Paget's Disease, Dermatofibroma, Kaposi's Sarcoma, Port Wine Stain, Hemangioma, Tattoos, Scleroderma, Burns
Interventions: Optical Biopsy imaging; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: Irvine, California

Conditions: Breast Cancer
Interventions: 3Dimensional Mammography, 2D FFDM; Device
Lead sponsor: Fujifilm Medical Systems USA, Inc.; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Rochester, New York

Conditions: Non Small-cell Lung Cancer
Interventions: Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule, Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection, Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer, Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease; Diagnostic Test
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Benign Neoplasm of True Vocal Cords
Interventions: absolute voice rest; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Neoplasms, Arteriovenous Malformation of Central Nervous System, Trigeminal Neuralgia
Interventions: SRS/SBRT; Radiation
Lead sponsor: The Radiosurgery Society; Other
Eligibility: Not listed
Enrollment: 50,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2030
U.S. locations: 13
States / cities: Colorado Springs, Colorado • Miami, Florida • Brunswick, Georgia + 10 more

Conditions: Breast Cancer
Interventions: Automated Breast Ultrasound (ABUS); Device
Lead sponsor: U-Systems, Inc.; Industry
Eligibility: Not listed
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Sunnyvale, California

Conditions: Thyroid Cancer, Thyroid Nodule, Benign Thyroid Nodule
Interventions: Emotionally Supportive Video, Standard Video; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Benign Neoplasms, In Situ Neoplasms, Malignant Neoplasms of Independent (Primary) Multiple Sites
Interventions: Questionnaires, Wearable Exercise Tracker Watch; Behavioral · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Esophageal Cancer, Bile Duct Neoplasms, Gastric Cancer, Liver Cancer, Melanoma, Pancreatic Cancer, Sarcoma
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Benign/Malignant Neoplasm, Long Bone Fracture
Interventions: propofol; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Low Risk, Papillary Thyroid Cancer, Radiofrequency Ablation
Interventions: Questionnaire; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated With Radiation

Bevacizumab and Radiation Therapy for Sarcomas

ARI103094-Follow-Up Study for REDUCE Study Subjects

Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules

Use of PET Imaging to Distinguish Malignant From Benign IPMN

Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings

Optical Biopsy of Human Skin in Conjunction With Laser Treatment

Collection of FUJIFILM's 3Dimensional Mammograms

Liquid Biopsy for Early Non-small Lung Cancer Detection

Impact of Duration Of Absolute Voice Rest on Voice Outcome After Phonomicrosurgery

RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT

CRRS-4 Pivotal Somo•v™ ABUS ROC Reader Observer Study

The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer

Wearable Exercise Trackers in Cancer Rehabilitation

Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract

Correlation of Bispectral Index Score and Total Intravenous Anesthesia (TIVA)

Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers